| 摘要 |
Compositions and methods useful for the identification of therapeutic agents useful for the treatment of T2D are disclosed. This invention relates to the fields of transcriptional regulation of metabolic disease and drug screening. More specifically, the invention provides the functional characterization of the transcriptional machinery bound across a TCF7L2 variant which plays a role in a variety of disorders, including without limitation, type 2 diabetes, cystic fibrosis related diabetes (CFRD), latent autoimmune diabetes in adults (LADA), gestational diabetes, islet antibody-negative diabetes in young patients, cardio- and micro-vascular disease and schizophrenia. |
